Get started
Author

Rimal Ilyas

Observed name: RIMAL ILYAS
OpenAlex ID: A5032076509
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
2023 · Naseema Gangat, Rimal Ilyas, et al. · Haematologica · 35
PDF
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
2022 · Naseema Gangat, Rimal Ilyas, et al. · Haematologica · 21
PDF
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
2023 · Rimal Ilyas, Kristen McCullough, et al. · Blood Cancer Journal · 11
PDF
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐ mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies
2024 · Naseema Gangat, Amritpal Singh, et al. · American Journal of Hematology · 8
PDF
Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
2022 · Isla McKerrow Johnson, Rimal Ilyas, et al. · Blood · 7
Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
2022 · Rimal Ilyas, Isla McKerrow Johnson, et al. · Blood · 6
Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
2022 · Naseema Gangat, Rimal Ilyas, et al. · Blood · 4
CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
2022 · Rimal Ilyas, Kristen McCullough, et al. · Blood · 4
Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
2025 · Isla M. Johnson, Rimal Ilyas, et al. · Haematologica · 3
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
2026 · Saubia Fathima, Lior Rokach, et al. · Blood Cancer Journal · 2
PDF
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
2023 · Mostafa Abdallah, Kristen McCullough, et al. · Blood Cancer Journal · 2
PDF
Comparative efficacy of idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma: Real-world analysis of overall survival and time to next treatment.
2025 · Eiraj Khan, Rimal Ilyas, et al. · Journal of Clinical Oncology · 1
PDF
A rare case of chronic lymphocytic leukemia complicated by myasthenia gravis
2025 · Eiraj Khan, Rimal Ilyas, et al. · Journal of Community Hospital Internal Medicine Perspectives · 1
PDF
The Cardiac Toll of CAR-T Therapy
2026 · Dawood Jamil, Eiraj Khan, et al. · Transplantation and Cellular Therapy
Impact of Atrial Fibrillation on 30-day Outcomes in Septic Shock: a Propensity-matched Analysis
2025 · IRFAN-UD-DIN MIAN, HASSAN KHALID, et al. · CHEST Journal
Comparative Outcomes of Nintedanib Vs Pirfernidone in Idiopathic Pulmonary Fibrosis: a Propensity-matched Analysis Over One and Three Years
2025 · PALWASHA ZAFAR, NAVNEET GUPTA, et al. · CHEST Journal
Impact of Social Determinants of Health on Copd Outcomes: a Propensity-matched Real-world Analysis
2025 · NAVNEET GUPTA, PALWASHA ZAFAR, et al. · CHEST Journal
Comparative Outcomes of Dupilumab and Tezepelumab in Asthma Management: a Real-world Analysis
2025 · PALWASHA ZAFAR, NAVNEET GUPTA, et al. · CHEST Journal
Real-World Outcomes of Primary and Secondary Plasma Cell Leukemia: A Single-Institution Retrospective Study
2025 · Kriti Dhamija, Rimal Ilyas, et al. · Clinical Lymphoma Myeloma & Leukemia
Real world analysis of MGUS: Risk of progression and overall survival.
2025 · Rimal Ilyas, Eiraj Khan, et al. · Journal of Clinical Oncology
A comparative analysis of outcomes following autologous hematopoietic cell transplantation in multiple myeloma patients with CRAB versus SLiM features.
2025 · Eiraj Khan, Abigail Arrigo, et al. · Journal of Clinical Oncology
Assessing the role of cytarabine-based regimens in mantle cell lymphoma: A real world study.
2025 · Yanal Mufeed Alnimer, Eiraj Khan, et al. · Journal of Clinical Oncology
PDF
Works count: 22
Citation count: 105
H-index: 6
I10-index: 3
Year
Topic
Type